Novartis, CH0012005267

Novartis stock trades at EUR 127.87 while volume is 21.5 percent below average

Published on 10/09/2026 at 15:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock costs EUR 127.87 on October 9, 2026 versus EUR 127.20. It is plus 0.53 percent, with volume at 1,532,573 shares on October 8.

Key points in brief

Novartis stock was trading at EUR 127.87 at Lang & Schwarz on October 9, 2026, plus 0.53 percent versus the prior close.
The NVS quote showed USD 143.11 on October 8, with a USD 121.57 to USD 170.46 52-week range.
Market capitalization was USD 272.0 billion and the price-to-earnings ratio was 21.86 as of October 8.
Novartis is scheduled to report third-quarter 2026 results on October 27, 2026.

Pop-Art-Illustration einer DNA-Doppelhelix mit Kapsel in leuchtendem Halftone-Raster — Novartis AG CH0012005267 – Pop-Art-Comic mit stilisierter DNA-Helix und Kapsel im bunten Halftone-Raster, Illustration mit AI erstellt.

At Lang & Schwarz, Novartis (ISIN CH0012005267) was trading at EUR 127.87 on October 9, 2026 at 3:18 p.m. CEST, plus 0.53 percent versus the prior close of EUR 127.20. The move was measured against a session that was still open for German investors.

Price and trading range

The latest NVS quote stood at USD 143.11 on October 8 at 4:00 p.m. ET. Its 52-week range was USD 121.57 to USD 170.46, putting the quote 16.05 percent below the high and 17.74 percent above the low.

Trading volume was 1,532,573 shares against an average of 1,952,354 shares on October 8. The latest volume was therefore 21.50 percent below the average, a useful liquidity marker alongside the EUR 127.87 Lang & Schwarz price.

Valuation remains measurable

Novartis had a market capitalization of USD 272.0 billion and a price-to-earnings ratio of 21.86 as of October 8. Its dividend yield was 3.00 percent in the same quote snapshot, while the company remained listed on the SIX Swiss Exchange under ticker NOVN.

Yahoo Finance lists revenue of USD 14.95 billion and earnings of USD 3.26 billion for the second quarter of fiscal 2026. The figures give the valuation a current operating reference without changing the euro price basis used in this report.

Comparison with peers

Novartis: plus 0.53 percent, P/E 21.86, market capitalization USD 272.0 billion

Roche Holding: minus 1.29 percent, P/E 23.40, market capitalization USD 340.2 billion

Johnson & Johnson: minus 0.76 percent, P/E 29.72, market capitalization USD 618.1 billion

Next results date is October 27

Novartis lists October 27, 2026 as the date for its financial results for the third quarter of 2026. That date provides the next fixed event for the stock after the October 9 price snapshot.

Euro price remains the reference

Novartis was trading at EUR 127.87 at Lang & Schwarz on October 9, 2026 at 3:18 p.m. CEST, plus 0.53 percent versus the Lang & Schwarz prior close of EUR 127.20. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.